Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Cardiovascular Drugs and Therapy|May 27, 2003
Specific drug delivery to the kidneyMarijke Haas, Frits Moolenaar, Dirk K F Meijer, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 27, 2005
Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in ratsJai Prakash, Vinay Saluja, Jan Visser, et al.Clinical Science (London, England : 1979)|March 15, 2003
Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic ratMarijke Haas, Eric de Boer, Paul E de Jong, et al.Journal of Drug Targeting|May 9, 2002
Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicityMarijke Haas, Frits Moolenaar, Angela Elsinga, et al.British Journal of Pharmacology|August 7, 2002
Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in ratsR Folgert G Haverdings, Marijke Haas, Gerjan Navis, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2005
Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozymeJai Prakash, Annemiek M van Loenen-Weemaes, Marijke Haas, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 2, 2005
Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosisWillemijn A K M Windt, Jai Prakash, Robbert Jan Kok, et al.Journal of the American Society of Nephrology : JASN|July 25, 2008
Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injuryJai Prakash, Martin H de Borst, Marie Lacombe, et al.Pharmaceutical Research|January 10, 2008
Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosisJai Prakash, Martin H de Borst, Annemiek M van Loenen-Weemaes, et al.The Journal of Pharmacology and Experimental Therapeutics|June 30, 2006
Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosisJai Prakash, Maria Sandovici, Vinay Saluja, et al.Pageof 1